Saturday 17 October 2026
Export ENSG’s income statement to Excel — free account
The Ensign Group, Inc.
ENSG Healthcare Medical Care Facilities
The Ensign Group, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 18.7% from fiscal 2024. In the quarter to June 2026, revenue grew 17.3%, EPS grew 16.2%, free cash flow grew 12.2% and total debt fell 2.77%, each against the same quarter a year earlier. Dividend growth for five consecutive years, revenue growth for five.
176.63
1.48
−0.83%
Follow ENSG
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
24.40 | 31.83 | 28.99 | 30.05 |
+8 more quarters Free account |
P/S ratio |
1.69 | 2.21 | 1.97 | 2.05 | |
P/FCF ratio |
22.17 | 28.67 | 26.93 | 34.56 | |
P/Operating CF |
54.03 | 116.23 | 54.46 | 64.80 | |
P/B ratio |
3.80 | 4.91 | 4.47 | 4.67 | |
Price to Tangible BV |
3.97 | 5.14 | 4.69 | 4.91 | |
EV/Sales |
1.66 | 2.12 | 1.89 | 1.98 | |
EV/EBITDA |
15.63 | 20.02 | 18.00 | 19.01 | |
EV/Operating CF |
14.97 | 18.89 | 16.93 | 19.84 | |
EV/FCF |
21.74 | 27.55 | 25.77 | 33.29 | |
Quick Ratio |
1.12 | 1.48 | 1.35 | 1.36 | |
Current Ratio |
1.21 | 1.56 | 1.42 | 1.46 | |
Net Debt/EBITDA |
(1.17) | (2.95) | (2.84) | (2.95) | |
Debt/Assets |
2.43% | 2.51% | 2.59% | 2.73% | |
Debt/Equity |
0.06 | 0.06 | 0.06 | 0.07 | |
Asset Turnover |
1.03 | 1.02 | 1.00 | 0.98 | |
Operating CF/Net income |
1.72 | 1.00 | 1.92 | 1.82 | |
Capex/Depreciation |
(1.67) | (1.22) | (1.79) | (1.90) | |
Interest Coverage |
63.38 | 64.62 | 63.33 | 48.82 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
5.96% | 5.34% | 5.20% | 5.20% | |
Intangible Assets out of Total Assets |
0.02 | 0.02 | 0.02 | 0.02 | |
Share Based Compensation of Revenue |
1.12% | 1.00% | 0.95% | 1.00% | |
Graham Net Nets |
(0.24) | (0.17) | (0.20) | (0.19) | |
Graham Number |
78.97 | 76.43 | 72.62 | 69.18 | |
Earnings Yield |
4.10% | 3.14% | 3.45% | 3.33% | |
Free Cash Flow Yield |
4.51% | 3.49% | 3.71% | 2.89% | |
Revenue per Share |
24.85 | 24.05 | 23.74 | 22.59 | |
Operating CF per Share |
2.97 | 1.73 | 3.20 | 2.67 | |
Capex per Share |
(0.91) | (0.61) | (0.87) | (0.89) | |
Free Cash Flow per Share |
2.06 | 1.12 | 2.33 | 1.78 | |
Cash per Share |
5.54 | 10.30 | 9.99 | 8.82 | |
Shareholders Equity per Share |
42.19 | 41.02 | 39.00 | 37.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
42.19 | 41.02 | 39.00 | 37.00 | |
Free Cash Flow |
119.13 | 64.68 | 133.35 | 101.93 | |
Working Capital |
186.69 | 472.05 | 377.96 | 381.35 | |
Capital Expenditures |
(52.83) | (35.47) | (49.97) | (51.07) | |
Net Current Asset Value |
(2,232.60) | (1,921.96) | (1,955.84) | (1,896.96) | |
EV/EBIT |
19.49 | 24.93 | 22.46 | 23.74 | |
Capex to Sales |
0.04 | 0.03 | 0.04 | 0.04 | |
Price to Operating Income |
19.88 | 25.94 | 23.47 | 24.64 | |
| Other line items | |||||
Average Receivables |
623.48 | 623.65 | 603.44 | 583.42 | |
Average Payables |
111.24 | 105.73 | 98.14 | 98.04 | |
Average Assets |
5,339.84 | 5,185.80 | 5,066.16 | 4,927.80 | |
Average Common Equity |
2,233.15 | 2,149.93 | 2,037.63 | 1,936.92 |
Columns are period end dates